• DocMorris raised its 2026 external revenue growth forecast to around 15%, from 12.5%-15%, driven by prescription medicines growth.
• Prescription revenue growth exceeded 90% year over year in October; full-year growth is expected at around 60%.
• Other annual and medium-term targets remain unchanged.
• The Medi24 acquisition is expected to contribute substantially to TeleClinic's EBITDA in 2027, supported by technology integration and operational synergies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DocMorris AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2432746_en) on November 12, 2026, and is solely responsible for the information contained therein.